Background: Ethanol (EtOH)-evoked oxidative stress, which contributes to myocardial dysfunction in proestrus rats, is mediated by increases in NADPH oxidase (Nox) activity, malondialdehyde (MDA), and ERK1/2 phosphorylation. Whether these biochemical responses, which are triggered by alcohol-derived acetaldehyde in noncardiac tissues, occur in proestrus rats' hearts remains unknown. Therefore, we elucidated the roles of alcohol dehydrogenase (ADH), cytochrome P4502E1 (CYP2E1), and catalase, which catalyze alcohol oxidation to acetaldehyde, in these alcohol-evoked biochemical and hemodynamic responses in proestrus rats.
A LCOHOL METABOLISM PLAYS an important role in organ injury, particularly through the generation of reactive oxygen species (ROS) (Zakhari, 2006) . Hepatic alcohol dehydrogenase (ADH), cytochrome P4502E1 (CYP2E1), and catalase, in other tissues such as brain (Zakhari, 2006) , are major enzymes that catalyze ethanol (EtOH) oxidation to a highly reactive and toxic metabolite, acetaldehyde. While EtOH-evoked oxidative stress is implicated in heart injury (Matyas et al., 2016; Piano, 2002; Piano and Phillips, 2014) , this evidence is based on chronic exposure to EtOH. It is noteworthy that our studies unraveled oxidative stressrelated myocardial dysfunction caused by acute EtOH only in the presence of endogenous estrogen (E 2 ) (El-Mas and Abdel-Rahman, 2014; Ibrahim et al., 2014; Yao and AbdelRahman, 2016) or exogenous E 2 administration to ovariectomized (OVX) (El-Mas and Abdel-Rahman, 2000) or male (El-Mas and Abdel-Rahman, 2015) rats. However, the role of these metabolizing enzymes in the alcohol-evoked myocardial oxidative stress/dysfunction in proestrus rats remains unknown.
EtOH-evoked increase in ADH catalytic activity is associated with increases in malondialdehyde (MDA) and ROS levels (El-Mas and Abdel-Rahman, 2014; Haorah et al., 2005; Hoek et al., 2002; Kalaz et al., 2012) . Notably, ROS is a product of oxidation of polyunsaturated fatty acids, and MDA level reflects lipid peroxidation (Grotto et al., 2009) . ADH inhibition abrogated EtOH-evoked oxidative stresses (Nishitani and Matsumoto, 2006) and protected hepatocytes from EtOH-induced apoptosis (Bailey and Cunningham, 1998) . Whether ADH inhibition protects against the acute EtOH-evoked myocardial dysfunction in female rats remains unknown. Besides ADH, the CYP2E1 plays an important role in EtOH oxidation in liver or other organs (Zimatkin and Deitrich, 1997; Zimatkin et al., 2006) . CYP2E1 activity is induced by chronic (Takahashi et al., 1993) or acute (Haorah et al., 2005) alcohol administration. Further, CYP2E1 inhibition, knockdown or knockout attenuated oxidative stress (Bardag-Gorce et al., 2000; Jin et al., 2013; Lu et al., 2008) , and myocardial contractile dysfunction (Zhang et al., 2013) caused by alcohol. Nonetheless, dual pharmacological inhibition of ADH and CYP2E1 by 4-methylpyrazole (4-MP) (Plumlee et al., 2005) may not be sufficient to fully inhibit EtOH oxidative metabolism in the presence of E 2 .
Catalase, the third enzyme that catalyzes EtOH oxidation to acetaldehyde (Zimatkin and Deitrich, 1997) , also serves an antioxidant role in many tissues including heart (Chelikani et al., 2004) . The latter role is consistent with the ability of catalase overexpression to protect against EtOHevoked dysfunction of myocytes isolated from male mice (Zhang et al., 2003) . By marked contrast, we showed that acute EtOH-evoked increase in cardiac catalase activity was associated with myocardia oxidative stress/dysfunction in E 2 replete rats (El-Mas and Abdel-Rahman, 2014; Ibrahim et al., 2014; Yao and Abdel-Rahman, 2016) . Based on these contradictory findings, it remains unknown whether catalase protects against or contributes to EtOH-evoked myocardial dysfunction in our model system. While sex difference and approaches (isolated myocytes vs. intact animal left ventricular [LV] function studies) must be considered, it is notable that pharmacological catalase inhibition reduced oxidation of alcohol (Thurman and Handler, 1989) , and attenuated EtOH-induced behavioral effects (Koechling and Amit, 1994; Pastor and Aragon, 2008) . Whether a similar pharmacological approach exacerbates or attenuates the E 2 -dependent myocardial oxidative stress/dysfunction in female rats has not been investigated.
The aim of this study was to elucidate the mechanistic roles of the EtOH metabolizing enzymes, ADH, CYP2E1, and catalase in the E 2 -dependent myocardial oxidative stress and dysfunction caused by acute EtOH in female rats.
MATERIALS AND METHODS

Animals
Female SD rats (200 to 250 g; Charles River, Raleigh, NC) were kept in the university animal care center at temperature of 23 AE 1°C, humidity of 50 AE 10%, and a 12-hour light/dark cycle and with access free to food (Prolab Rodent Chow; Granville Milling, Creedmoor, NC) and water. The surgical and animal care procedures were approved by the East Carolina University Institutional Animal Care and Use Committee and were consistent with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) .
Catheterization
The animals were anesthetized by the mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg, intraperitoneal [i.p.] ). Vascular and LV catheterizations were performed as detailed in our recent study Abdel-Rahman, 2016, 2017) under sterile conditions. Briefly, heparinized arterial/venous catheters (Konigsberg Instruments Inc., Pasadena, CA) were placed into the abdominal aorta/vena cava via the femoral artery/vein for monitoring blood pressure (BP) and administering the pharmacological intervention (EtOH metabolizing enzyme inhibitors, EtOH or saline), respectively. The rats received buprenorphine (0.03 mg/kg, subcutaneous) for postoperative analgesia.
Hemodynamic Recording
LV function and BP measurements were conducted in conscious freely moving rats as detailed in our previous studies (Ibrahim et al., 2014; Abdel-Rahman, 2016, 2017) . BP and LV indices were simultaneously recorded by ML870 (PowerLab 8/30; ADInstruments, Inc., Colorado Springs, CO) via Gould-Statham pressure transducers (Oxnard, CA).
Plasma EtOH Concentration
The whole blood was centrifuged, and the plasma was collected for measurement of EtOH concentration as descripted in our previous studies (El-Mas et al., 2008; Abdel-Rahman, 2016, 2017) . The reaction between EtOH and ADH took place in a 96-well plate. An Infinite Ò 200 PRO multimode microplate reader (Tencan Group Ltd., M€ annedorf, Switzerland) was used to detect the absorbance at 340 nm.
ROS Level
We followed the methods in our previous studies (McGee and Abdel-Rahman, 2012; Abdel-Rahman, 2016, 2017) . The supernatant of the homogenized myocardial tissue was used to measure the ROS formation by a fluorometric assay using DCFH-DA (Molecular Probes-Thermo Fisher Scientific Inc., Raleigh, NC). The fluorescence intensities were read at 485/530 nm (excitation/ emission) with Infinite Ò 200 PRO multimode microplate readers (Tencan Group Ltd.) at 37°C.
NADPH Oxidase Activity
As described in a previous study (La Favor et al., 2013) , 20 ll supernatant of the homogenized LV tissue (100 lg protein)/standard was incubated with 10 lM Amplex Red (Molecular Probes, Eugene, OR), 2.0 U/ml horseradish peroxidase, 30 U/ml superoxide dismutase, and 100 lM NADPH (Sigma-Aldrich, St. Louis, MO) for 90 minutes at 37°C. Fluorescence intensity (530 nM ex/ 590 nM em) was measured.
MDA Level
As described in our previous studies Abdel-Rahman, 2016, 2017) , TBARS Assay Kit (Cayman Chemical, Ann Arbor, MI) was used for measuring MDA levels. The MDA-TBA adduct was measured colorimetrically at 530 to 540 nm.
Western Blot
We followed the protocols described in our studies (Ibrahim et al., 2014; Abdel-Rahman, 2016, 2017) . The supernatant (40 lg of protein) of the homogenized LV tissue was separated in a 4 to 12% gel electrophoresis (Novex Tis-Glycine gel; Life Technologies, Camarillo, CA), and transferred to nitrocellulose membrane, and then incubated with a primary antibody (mouse anti-p-ERK1/2 and rabbit anti-ERK1/2; 1:500; Cell Signaling, Danvers, MA). Thereafter, the membrane was incubated with a secondary antibody (IRDye680-conjugated goat anti-mouse and IRDye800-conjugated goat anti-rabbit, 1:15,000; LI-COR Biosciences, Lincoln, NE), and the protein bands were detected and quantified by Odyssey Infrared Imager (LI-COR Biosciences). Ibrahim et al., 2014; Yao and Abdel-Rahman, 2016) . Here, we investigated the effect of the ADH and CYP2E1 inhibitor 4-MP (Knoester et al., 2002) , the catalase inhibitor 3-Amino-1,2,4-triazole (3-AT) (Correa et al., 2008) , or their combination on the EtOHevoked myocardial dysfunction in proestrus rats. The proestrus phase, determined by vaginal smear (Marcondes et al., 2001) , coincides with the highest endogenous plasma E 2 levels (El-Mas and Abdel-Rahman, 2014). Fifty-two female SD rats, divided into 8 groups (5 to 8 rats/group), were used in this experiment. The LV function and BP were measured in conscious rats 2 days after LV and femoral vascular catheterization. At least 30 minutes was allowed for stabilization of the measured variables. The 8 groups were divided into 4 pairs with each pair receiving 4-MP (82 mg/kg, i.p.), 3-AT (0.5 g/kg, intravenous [i.v.]), their combination or saline 30 minutes before i.v. infusion of EtOH (1.5 g/kg), delivered as 0.39 ml of 50% EtOH per 100 g body weight over 30 minutes, or equal volume of saline. The dose of 4-MP (Jamal et al., 2007; Waller et al., 1982 ) and 3-AT (Correa et al., 2008) was based on reported studies. The EtOH regimen was based on our studies (ElMas and Abdel-Rahman, 2014, 2015) . Mean arterial pressure (MAP), LVDP, and maximum rate of LV pressure rise (dP/dt max ) were recorded for 90 minutes. Blood samples were collected before any treatment and at 30, 60, and 90 minutes after EtOH or saline infusion. At the end of the hemodynamic measurements, all rats were euthanized, and the hearts were collected for conducting the ex vivo biochemical studies.
Experiment 2. Effect of ADH, CYP2E1, or Catalase Inhibition on Blood EtOH Level and Mediators of Myocardial Oxidative Stress
Caused by EtOH. In these ex vivo biochemical studies, we measured the time-course changes in blood EtOH concentration (BAC) in EtOH-treated rats in the absence or presence of the enzyme inhibitors, 4-MP, 3-AT, or their combination. Further, we measured ROS, MDA, NADPH oxidase (Nox) activity, ERK1/2 phosphorylation level in the hearts of the treatment and control groups used in the study under experiment 1, above.
Drugs
EtOH was purchased from Midwest Grain Products Co. (Weston, MO) and diluted in saline. 3-AT and 4-MP (Sigma-Aldrich) were dissolved in saline.
Data Analysis and Statistics
The hemodynamic responses caused by pretreatment with the inhibitor(s) of EtOH metabolizing enzymes were analyzed by 2-tailed t-test versus their vehicle, saline ( Table 1 ). The areas under the curve for hemodynamic indices and the biochemical data were analyzed by 1-way analysis of variance (ANOVA) followed by post hoc Tukey's t-test comparison and Bonferroni correction when the pairwise t-tests were performed. The statistical analysis was conducted with Prism version 5 (GraphPad Software, Inc. La Jolla, CA). Values are presented as mean AE SEM. p < 0.05 was considered significant.
RESULTS
Inhibition of ADH and CYP2E1 (4-MP), Catalase (3-AT), or Their Combination Mitigated EtOH-Evoked Myocardial Dysfunction in Proestrus Rats
Inhibition of ADH and CYP2E1 by 4-MP alone had no effect on all hemodynamic indices. However, catalase inhibition alone (3-AT) or in combination with 4-MP reduced (p < 0.05) myocardial function (dP/dt max , LVDP) and MAP (Table 1 ). In saline (vehicle for enzyme inhibitors)-pretreated rats, EtOH (1.5 g/kg) reduced (p < 0.05) dP/dt max , LVDP, and MAP (Figs 1-3) . Pretreatment with 4-MP or 3-AT partially, while their combination significantly (p < 0.05), attenuated these adverse hemodynamic effects of EtOH (Fig. 1E,F) .
The Effect of 4-MP, 3-AT, or Their Combination on Blood EtOH
BAC reached 131 AE 8.2 mg/dl at 30 minutes after EtOH (1.5 g/kg) infusion and then dropped to 104.8 AE 8.7 and 98.3 AE 5.9 mg/dl at 60 and 90 minutes, respectively (Fig. 4A) . However, BAC was higher (p < 0.05) in rats pretreated with 4-MP or 3-AT and synergistically increased by their combination (Fig. 4) . 
Inhibition of ADH and CYP2E1 (4-MP), Catalase (3-AT), or Their Combination Abrogated EtOH-Evoked Myocardial Oxidative Stress in Proestrus Rats
EtOH increased (p < 0.05) ROS level (Fig. 5A ), Nox activity (Fig. 5B ), ERK1/2 phosphorylation (Fig. 6) , and MDA level (Fig. 7A) in the hearts as well as MDA level in plasma (Fig. 7B ) of proestrus rats. These EtOH-evoked biochemical responses, which reflect oxidative stress, were abrogated in rats pretreated with 4-MP, 3-AT, or their combination (Figs 5 and 7) . Notably, catalase inhibition (3-AT) increased (p < 0.05) myocardial ROS level, Nox activity, and ERK1/2 phosphorylation as well as plasma MDA levels (Figs 5-7) . However, 4-MP, 3-AT, or their combination reduced (p < 0.05) myocardial MDA levels (Fig. 7A) . Despite this significant (p < 0.05) reduction in cardiac or elevation in plasma MDA levels, caused by combining 4-MP and 3-AT, subsequent EtOH administration reduced (p < 0.05) cardiac (Fig. 7A) and plasma (Fig. 7B ) MDA levels. Collectively, the attenuation of the EtOHevoked increases in mediators of oxidative stress by 4-MP, 3-AT, or their combination (Figs 5-7) paralleled the abrogation of reductions in myocardial function in the same rats (Figs 1 and 2) .
DISCUSSION
The present study generated important data on the roles of 3 EtOH metabolizing enzymes, ADH, CYP2E1, and catalase, in myocardial oxidative stress/dysfunction caused by acute EtOH in E 2 replete female rats. We show that ADH and CYP2E1 (4-MP) or catalase (3-AT) inhibition partially, while their combination drastically, attenuated the EtOH-evoked deleterious cardiac effects. The results of our ex vivo biochemical studies suggest an important role for the first oxidative metabolite of EtOH in triggering mediators of myocardial oxidative stress. The latter is a major contributor to the E 2 -dependent myocardial dysfunction caused by alcohol. It is imperative to be cognizant of the induction of cardiac oxidative stress and the hypotension caused by 3-AT when interpreting the present findings.
We documented a pivotal role for myocardial oxidative stress in the sex/E 2 -dependent myocardial dysfunction caused by acute EtOH administration in proestrus rats (El-Mas and Abdel-Rahman, 2014; Ibrahim et al., 2014; Yao and Abdel-Rahman, 2016) . Realizing that acetaldehyde, the first EtOH oxidative metabolite, causes MAPK-dependent oxidative stress in many tissues (Ku et al., 2007; Yan et al., 2016) , it was important to elucidate the role of this metabolic pathway in EtOH-evoked myocardial dysfunction. However, we needed to consider the possibility that this metabolic pathway is not involved in this deleterious cardiac effect of EtOH because acetaldehyde generation does not explain some effects of EtOH in other tissues (Czech and Hartleb, 2002; Haber et al., 2004; Manautou et al., 1992) , and catalase overexpression protects against EtOH-evoked dysfunction of isolated cardiac myocytes (Yao et al., 2015) . Therefore, it was important to study, for the first time, the consequences of inhibiting ADH, CYP2E1, and catalase, which catalyze EtOH metabolism to acetaldehyde (Zakhari, 2006) in our model system. We administered 4-MP, an inhibitor of both ADH and CYP2E1 (Knoester et al., 2002) ; 3-AT, an inhibitor of catalase (Correa et al., 2008) ; alone or in combination. This approach permitted evaluation of the contribution of the 3 EtOH metabolizing enzymes to the EtOH-evoked myocardial dysfunction.
In support of our hypothesis, EtOH-evoked myocardial dysfunction was attenuated by prior inhibition of ADH and CYP2E (4-MP) or catalase (3-AT) and virtually abolished by their combination (Figs 1-3) . The parallel attenuation of EtOH-evoked increases in oxidative stress (ROS), and related molecular events (MDA; ERK1/2 phosphorylation) (Figs 5-7) suggest mechanistic roles for these biochemical effects in EtOH-evoked myocardial dysfunction and its rescue following the inhibition of EtOH oxidative metabolism. This protective effect resembles protection against EtOHevoked apoptosis in hepatocytes (Bailey and Cunningham, 1998) by ADH inhibition (Nishitani and Matsumoto, 2006) via reducing EtOH-elicited oxidative stresses (Bailey and Cunningham, 1998) . Further, genetic and pharmacological CYP2E1 inhibition attenuated chronic EtOH-induced myocardial contractile dysfunction in mice (Zhang et al., 2013) , but these studies were conducted in vitro on myocytes isolated from male mice. Finally, pharmacological inhibition of catalase depressed oxidation of alcohol (Thurman and Handler, 1989) and prevented EtOH-induced behavioral stimulation (Pastor and Aragon, 2008) and motivation for alcohol consumption (Koechling and Amit, 1994) . However, the effects of catalase inhibition on the E 2 -dependent myocardial oxidative stress and dysfunction have not been investigated.
The present study further supports the role of catalase in our model system because reported studies, including ours, show that E 2 enhances catalase catalytic activity in the heart of female rats (Campos et al., 2014; El-Mas and Abdel-Rahman, 2014; Ibrahim et al., 2014; Yao and Abdel-Rahman, 2016) . Further, acute EtOH causes additional increase in cardiac catalase activity in the presence of E 2 receptor-alpha activation along with myocardial oxidative stress and dysfunction (Yao and Abdel-Rahman, 2017) . The ability of catalase inhibition (3-AT) to attenuate EtOH-evoked LV dysfunction (Figs 1 and 2 ) and oxidative stress (Figs 5 and 7) supports a contributory role for catalase in these adverse effects. The partial attenuation of the EtOH-evoked myocardial dysfunction (dP/dt max and LVDP) by 3-AT or 4-MP (Figs 1 and 2 ) might be explained by: (i) the ability of the available enzyme(s) to compensate for the inhibited enzyme (s) or (ii) the higher BAC achieved (Fig. 4) because alcohol itself exerts direct cardiotoxic effect (Awtry and Philippides, 2010) . Notably, the accumulation of nonoxidative EtOH metabolites such as fatty acid ethyl ester in blood (Doyle et al., 1994) and heart (Laposata and Lange, 1986 ) is increased following inhibition of EtOH oxidative metabolism (Werner et al., 2002) . The present findings argue against the contribution of these alternative mechanisms because combined enzyme inhibition (3-AT plus 4-MP) conferred much better hemodynamic protection (Fig. 2) . Interestingly, in these rats, the synergistically higher BAC (Fig. 5 ) correlated with substantial reductions in cardiac and plasma MDA levels (Fig. 7) . While MDA reduction might explain the improved cardiac function, it remains to be determined how EtOH-evoked increase in MDA observed here and in our previous studies (Ibrahim et al., 2014) is reversed in the presence of combined ADH, CYP2E1, and catalase inhibition (Fig. 7) .
The present study provides physiologically relevant data with catalase inhibition in the absence of EtOH. Consistent with its antioxidant role (Chelikani et al., 2004) , and the ability of catalase inhibition to increase ROS production in isolated ventricular myocytes (Boles et al., 2014) , 3-AT caused myocardial oxidative stress (higher ROS) level (Fig. 5A) , at least partly, via enhanced Nox activity (Fig. 5B ) and ERK1/ 2 phosphorylation (Fig. 6) . Further, a central mechanism might play a role in the reduced BP because injection of 3-AT into the fourth ventricle (Valenti et al., 2010) or nucleus tractus solitarius (Cardoso et al., 2009 ) decreases BP in conscious rats. We also showed that 3-AT significantly increased plasma MDA level (Fig. 7B) , which is consistent with higher plasma MDA in patients with lower catalase activity (Begenik et al., 2013) . Notably, the inconsistency between lower myocardial and higher plasma MDA levels following 4-MP, 3-AT, or their combination (Fig. 7A ) also exists between lower liver and higher plasma MDA levels in reported studies (El-Bassiouni et al., 1998) .
It is imperative to consider the impact of the biochemical and hemodynamic effects of 3-AT, given alone or with 4-MP, on data interpretation. First, while statistically nonsignificant, the reductions in LVDP and dP/dt max caused by 3-AT might limit, at least partly, the EtOH-evoked LV dysfunction. This possibility is supported by the inability of EtOH to reduce BP when BP was significantly reduced in rats pretreated with 3-AT alone or in combination with 4-MP. Second, the 3-AT evoked increases in ROS and MDA levels, Nox activity, and ERK1/2 phosphorylation might have limited the EtOH-evoked increases in these mediators of oxidative stress. Notably, the abrogation of the EtOH-evoked increases in ROS level and Nox activity despite a lack of change in their basal levels, in 4-MP-pretreated rats, argues against this possibility. Further, we observed unexplained reductions in cardiac MDA caused by 4-MP, 3-AT, and their combination and an additional reduction in rats treated with both inhibitors and EtOH (Fig. 7) . Further studies are needed to elucidate the mechanisms of these biochemical effects caused by these enzyme inhibitors and EtOH.
The current study yields a novel insight into the role of EtOH oxidative metabolism in myocardial dysfunction caused by EtOH via accumulation of cardiotoxic molecules (ROS and MDA). While inhibiting ADH and CYP2E1 (4-MP), catalase (3-AT), or their combination substantially increased BAC (Fig. 4) , this pharmacological approach abrogated the EtOH-evoked increases in cardiac Nox activity, ROS and MDA levels, and ERK1/2 phosphorylation. The findings support the contribution of these molecules, generated via oxidative metabolism of EtOH, to EtOH-evoked myocardial dysfunction in female rats.
Nonetheless, at the doses used in behavioral studies, the enzyme inhibitors (3-AT and 4-MP) exerted biochemical and cardiovascular effects that might have influenced data interpretation.
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